Skip to main content
NCBI home page
Emerging Infectious Diseases logoLink to Emerging Infectious Diseases
. 1996 Jul-Sep;2(3):200–208. doi: 10.3201/eid0203.960306

Antibody-based therapies for emerging infectious diseases.

A Casadevall 1
PMCID: PMC2626792  PMID: 8903230

Abstract

In the 19th century, it was discovered that immune sera were useful in treating infectious diseases. Serum therapy was largely abandoned in the 1940s because of the toxicity associated with the administration of heterologous sera and the introduction of effective antimicrobial chemotherapy. Recent advances in the technology of monoclonal antibody production provide the means to generate human antibody reagents and reintroduce antibody therapies, while avoiding the toxicities associated with serum therapy. Because of the versatility of antibodies, antibody-based therapies could, in theory, be developed against any existing pathogen. The advantages of antibody-based therapies include versatility, low toxicity, pathogen specificity, enhancement of immune function, and favorable pharmacokinetics; the disadvantages include high cost, limited usefulness against mixed infections, and the need for early and precise microbiologic diagnosis. The potential of antibodies as antiinfective agents has not been fully tapped. Antibody-based therapies constitute a potentially useful option against newly emergent pathogens.

Full Text

The Full Text of this article is available as a PDF (345.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barnes G. L., Doyle L. W., Hewson P. H., Knoches A. M., McLellan J. A., Kitchen W. H., Bishop R. F. A randomised trial of oral gammaglobulin in low-birth-weight infants infected with rotavirus. Lancet. 1982 Jun 19;1(8286):1371–1373. doi: 10.1016/s0140-6736(82)92496-5. [DOI] [PubMed] [Google Scholar]
  2. Berkelman R. L., Bryan R. T., Osterholm M. T., LeDuc J. W., Hughes J. M. Infectious disease surveillance: a crumbling foundation. Science. 1994 Apr 15;264(5157):368–370. doi: 10.1126/science.8153621. [DOI] [PubMed] [Google Scholar]
  3. Bodmer M., Fournel M. A., Hinshaw L. B. Preclinical review of anti-tumor necrosis factor monoclonal antibodies. Crit Care Med. 1993 Oct;21(10 Suppl):S441–S446. doi: 10.1097/00003246-199310001-00005. [DOI] [PubMed] [Google Scholar]
  4. Borowitz S. M., Saulsbury F. T. Treatment of chronic cryptosporidial infection with orally administered human serum immune globulin. J Pediatr. 1991 Oct;119(4):593–595. doi: 10.1016/s0022-3476(05)82412-6. [DOI] [PubMed] [Google Scholar]
  5. Casadevall A. Antibody immunity and invasive fungal infections. Infect Immun. 1995 Nov;63(11):4211–4218. doi: 10.1128/iai.63.11.4211-4218.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Casadevall A., Scharff M. D. Return to the past: the case for antibody-based therapies in infectious diseases. Clin Infect Dis. 1995 Jul;21(1):150–161. doi: 10.1093/clinids/21.1.150. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Casadevall A., Scharff M. D. Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrob Agents Chemother. 1994 Aug;38(8):1695–1702. doi: 10.1128/aac.38.8.1695. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Conti D. J., Freed B. M., Gruber S. A., Lempert N. Prophylaxis of primary cytomegalovirus disease in renal transplant recipients. A trial of ganciclovir vs immunoglobulin. Arch Surg. 1994 Apr;129(4):443–447. doi: 10.1001/archsurg.1994.01420280121016. [DOI] [PubMed] [Google Scholar]
  9. Delaet I., Boeyé A. Monoclonal antibodies that disrupt poliovirus only at fever temperatures. J Virol. 1993 Sep;67(9):5299–5302. doi: 10.1128/jvi.67.9.5299-5302.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Devi S. J., Schneerson R., Egan W., Ulrich T. J., Bryla D., Robbins J. B., Bennett J. E. Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity. Infect Immun. 1991 Oct;59(10):3700–3707. doi: 10.1128/iai.59.10.3700-3707.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Dromer F., Charreire J. Improved amphotericin B activity by a monoclonal anti-Cryptococcus neoformans antibody: study during murine cryptococcosis and mechanisms of action. J Infect Dis. 1991 May;163(5):1114–1120. doi: 10.1093/infdis/163.5.1114. [DOI] [PubMed] [Google Scholar]
  12. Fink M. P. Adoptive immunotherapy of gram-negative sepsis: use of monoclonal antibodies to lipopolysaccharide. Crit Care Med. 1993 Feb;21(2 Suppl):S32–S39. doi: 10.1097/00003246-199302001-00007. [DOI] [PubMed] [Google Scholar]
  13. Flexner S. THE RESULTS OF THE SERUM TREATMENT IN THIRTEEN HUNDRED CASES OF EPIDEMIC MENINGITIS. J Exp Med. 1913 May 1;17(5):553–576. doi: 10.1084/jem.17.5.553. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. French D. L., Laskov R., Scharff M. D. The role of somatic hypermutation in the generation of antibody diversity. Science. 1989 Jun 9;244(4909):1152–1157. doi: 10.1126/science.2658060. [DOI] [PubMed] [Google Scholar]
  15. Friden P. M., Walus L. R., Musso G. F., Taylor M. A., Malfroy B., Starzyk R. M. Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4771–4775. doi: 10.1073/pnas.88.11.4771. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Halter R., Pohlner J., Meyer T. F. Mosaic-like organization of IgA protease genes in Neisseria gonorrhoeae generated by horizontal genetic exchange in vivo. EMBO J. 1989 Sep;8(9):2737–2744. doi: 10.1002/j.1460-2075.1989.tb08415.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Isaacs J. D., Watts R. A., Hazleman B. L., Hale G., Keogan M. T., Cobbold S. P., Waldmann H. Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet. 1992 Sep 26;340(8822):748–752. doi: 10.1016/0140-6736(92)92294-p. [DOI] [PubMed] [Google Scholar]
  18. Joshi N., Milfred D. The use and misuse of new antibiotics. A perspective. Arch Intern Med. 1995 Mar 27;155(6):569–577. [PubMed] [Google Scholar]
  19. Köhler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975 Aug 7;256(5517):495–497. doi: 10.1038/256495a0. [DOI] [PubMed] [Google Scholar]
  20. Lang A. B., Cryz S. J., Jr, Schürch U., Ganss M. T., Bruderer U. Immunotherapy with human monoclonal antibodies. Fragment A specificity of polyclonal and monoclonal antibodies is crucial for full protection against tetanus toxin. J Immunol. 1993 Jul 1;151(1):466–472. [PubMed] [Google Scholar]
  21. Lazarovits A. I., Rochon J., Banks L., Hollomby D. J., Muirhead N., Jevnikar A. M., White M. J., Amlot P. L., Beauregard-Zollinger L., Stiller C. R. Human mouse chimeric CD7 monoclonal antibody (SDZCHH380) for the prophylaxis of kidney transplant rejection. J Immunol. 1993 Jun 1;150(11):5163–5174. [PubMed] [Google Scholar]
  22. LoBuglio A. F., Wheeler R. H., Trang J., Haynes A., Rogers K., Harvey E. B., Sun L., Ghrayeb J., Khazaeli M. B. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci U S A. 1989 Jun;86(11):4220–4224. doi: 10.1073/pnas.86.11.4220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Mazanec M. B., Kaetzel C. S., Lamm M. E., Fletcher D., Nedrud J. G. Intracellular neutralization of virus by immunoglobulin A antibodies. Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):6901–6905. doi: 10.1073/pnas.89.15.6901. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Mineo J. R., Khan I. A., Kasper L. H. Toxoplasma gondii: a monoclonal antibody that inhibits intracellular replication. Exp Parasitol. 1994 Nov;79(3):351–361. doi: 10.1006/expr.1994.1097. [DOI] [PubMed] [Google Scholar]
  25. Mukherjee J., Feldmesser M., Scharff M. D., Casadevall A. Monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole efficacy. Antimicrob Agents Chemother. 1995 Jul;39(7):1398–1405. doi: 10.1128/aac.39.7.1398. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Mukherjee J., Scharff M. D., Casadevall A. Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect Immun. 1992 Nov;60(11):4534–4541. doi: 10.1128/iai.60.11.4534-4541.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Mukherjee J., Zuckier L. S., Scharff M. D., Casadevall A. Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B. Antimicrob Agents Chemother. 1994 Mar;38(3):580–587. doi: 10.1128/aac.38.3.580. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Munford R. S., Murphy T. V. Antimicrobial resistance in Streptococcus pneumoniae: can immunization prevent its spread? J Investig Med. 1994 Dec;42(4):613–621. [PubMed] [Google Scholar]
  29. Pasatiempo A. M., Kroser J. A., Rudnick M., Hoffman B. I. Acute renal failure after intravenous immunoglobulin therapy. J Rheumatol. 1994 Feb;21(2):347–349. [PubMed] [Google Scholar]
  30. Pennington J. E. Newer uses of intravenous immunoglobulins as anti-infective agents. Antimicrob Agents Chemother. 1990 Aug;34(8):1463–1466. doi: 10.1128/aac.34.8.1463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Pier G. B., Thomas D., Small G., Siadak A., Zweerink H. In vitro and in vivo activity of polyclonal and monoclonal human immunoglobulins G, M, and A against Pseudomonas aeruginosa lipopolysaccharide. Infect Immun. 1989 Jan;57(1):174–179. doi: 10.1128/iai.57.1.174-179.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Reilly R. M., Sandhu J., Alvarez-Diez T. M., Gallinger S., Kirsh J., Stern H. Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions. Clin Pharmacokinet. 1995 Feb;28(2):126–142. doi: 10.2165/00003088-199528020-00004. [DOI] [PubMed] [Google Scholar]
  33. Roilides E., Pizzo P. A. Modulation of host defenses by cytokines: evolving adjuncts in prevention and treatment of serious infections in immunocompromised hosts. Clin Infect Dis. 1992 Sep;15(3):508–524. doi: 10.1093/clind/15.3.508. [DOI] [PubMed] [Google Scholar]
  34. Schroff R. W., Foon K. A., Beatty S. M., Oldham R. K., Morgan A. C., Jr Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res. 1985 Feb;45(2):879–885. [PubMed] [Google Scholar]
  35. Sekul E. A., Cupler E. J., Dalakas M. C. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med. 1994 Aug 15;121(4):259–262. doi: 10.7326/0003-4819-121-4-199408150-00004. [DOI] [PubMed] [Google Scholar]
  36. Service R. F. Antibiotics that resist resistance. Science. 1995 Nov 3;270(5237):724–727. doi: 10.1126/science.270.5237.724. [DOI] [PubMed] [Google Scholar]
  37. Slade H. B. Human Immunoglobulins for intravenous use and hepatitis C viral transmission. Clin Diagn Lab Immunol. 1994 Nov;1(6):613–619. doi: 10.1128/cdli.1.6.613-619.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Smith T. W., Butler V. P., Jr, Haber E., Fozzard H., Marcus F. I., Bremner W. F., Schulman I. C., Phillips A. Treatment of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments: experience in 26 cases. N Engl J Med. 1982 Nov 25;307(22):1357–1362. doi: 10.1056/NEJM198211253072201. [DOI] [PubMed] [Google Scholar]
  39. Sădziene A., Rosa P. A., Thompson P. A., Hogan D. M., Barbour A. G. Antibody-resistant mutants of Borrelia burgdorferi: in vitro selection and characterization. J Exp Med. 1992 Sep 1;176(3):799–809. doi: 10.1084/jem.176.3.799. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Triguero D., Buciak J. B., Yang J., Pardridge W. M. Blood-brain barrier transport of cationized immunoglobulin G: enhanced delivery compared to native protein. Proc Natl Acad Sci U S A. 1989 Jun;86(12):4761–4765. doi: 10.1073/pnas.86.12.4761. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Waldmann T. A., Strober W. Metabolism of immunoglobulins. Prog Allergy. 1969;13:1–110. doi: 10.1159/000385919. [DOI] [PubMed] [Google Scholar]
  42. Watson D. A., Musher D. M., Jacobson J. W., Verhoef J. A brief history of the pneumococcus in biomedical research: a panoply of scientific discovery. Clin Infect Dis. 1993 Nov;17(5):913–924. doi: 10.1093/clinids/17.5.913. [DOI] [PubMed] [Google Scholar]
  43. Weisman L. E., Cruess D. F., Fischer G. W. Opsonic activity of commercially available standard intravenous immunoglobulin preparations. Pediatr Infect Dis J. 1994 Dec;13(12):1122–1125. doi: 10.1097/00006454-199412000-00010. [DOI] [PubMed] [Google Scholar]
  44. Wolff S. M. Monoclonal antibodies and the treatment of gram-negative bacteremia and shock. N Engl J Med. 1991 Feb 14;324(7):486–488. doi: 10.1056/NEJM199102143240709. [DOI] [PubMed] [Google Scholar]
  45. Wolff S. N., Fay J. W., Herzig R. H., Greer J. P., Dummer S., Brown R. A., Collins R. H., Stevens D. A., Herzig G. P. High-dose weekly intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy. A study of the American Bone Marrow Transplant Group. Ann Intern Med. 1993 Jun 15;118(12):937–942. doi: 10.7326/0003-4819-118-12-199306150-00004. [DOI] [PubMed] [Google Scholar]
  46. Wright A., Shin S. U., Morrison S. L. Genetically engineered antibodies: progress and prospects. Crit Rev Immunol. 1992;12(3-4):125–168. [PubMed] [Google Scholar]
  47. Yanase K., Smith R. M., Cizman B., Foster M. H., Peachey L. D., Jarett L., Madaio M. P. A subgroup of murine monoclonal anti-deoxyribonucleic acid antibodies traverse the cytoplasm and enter the nucleus in a time-and temperature- dependent manner. Lab Invest. 1994 Jul;71(1):52–60. [PubMed] [Google Scholar]
  48. Zuckier L. S., Rodriguez L. D., Scharff M. D. Immunologic and pharmacologic concepts of monoclonal antibodies. Semin Nucl Med. 1989 Jul;19(3):166–186. doi: 10.1016/s0001-2998(89)80012-1. [DOI] [PubMed] [Google Scholar]

Articles from Emerging Infectious Diseases are provided here courtesy of Centers for Disease Control and Prevention

RESOURCES